Journal article
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus
GV Matthews, EC Seaberg, A Avihingsanon, S Bowden, GJ Dore, SR Lewin, J Sasadeusz, PA Revill, M Littlejohn, JF Hoy, R Finlayson, K Ruxrungtham, M Saulynas, S Locarnini, CL Thio
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2013
DOI: 10.1093/cid/cit002
Abstract
Background. Tenofovir (TDF) is effective for treatment of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) infection; however, some individuals have ongoing HBV viremia, the reasons for which are unclear. We determined the patterns and factors associated with detectable HBV DNA in HIV-HBV-coinfected subjects on highly active antiretroviral therapy (HAART).Methods. One hundred sixty-five HIV-HBV-coinfected individuals from the United States, Australia, and Thailand, the majority of whom were on HAART at study entry, were prospectively followed semiannually for a median of 2.8 years. Logistic regression was used to determine factors associated with detectable HBV DNA.Results. Anti..
View full abstractRelated Projects (1)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by the National Institutes of Health (grant number R56AI60449). K. R. has been awarded Senior Researcher Scholar, Thai Research Fund; the National Research University Project of CHE (HR1161A), Ministry of Education; and the Professional Research Team Strengthening Fund, from the National Science and Technology Development Agency, BIOTEC, Ministry of Science and Technology, Thailand. The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute. UO1-AI-35042, UL1-RR025005, UO1-AI-35043, UO1-AI-35039, UO1-AI-35040, UO1-AI-35041.